IONS Stock Ionis Pharmaceuticals, Inc.
BUY US · NasdaqGSLate-stage pipeline optionality and substantial consensus upside create a compelling biotechnology setup.
Future value: $83.26 (+91.75%) · 6-12 months
Signal breakdown
- ▸Analyst Buy ratings and high consensus price target.
- ▾Below 50-day MA (-13.57%)
- ▾Near 52-week low (3% of range)
- ▸~92% upside to price target
Is IONS a buy right now?
Trend: IONS is trading below the 50-day average (-13.57%), RSI 34 — neutral momentum, with a 3-month return of -21.48%.
Valuation & quality: Ionis Pharmaceuticals, Inc. trades on forward P/E -37.9, PEG 27.33, price-to-book 16.35; fundamentals show net margin -64.7%, return on equity -105.5%, revenue growth -40.7% year on year.
Analyst consensus: 23 analysts have a mean 12-month price target of $84.13 (+93.8% vs the last close; range $58.00 – $105.00), consensus rating “buy”.
Our screen: BUY (score 3) — Late-stage pipeline optionality and substantial consensus upside create a compelling biotechnology setup.
Computed from end-of-day data; not personal advice.
Our track record with IONS
First flagged in our daily picks as BUY on 2026-10-27 at $43.42.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -7.50% | -0.40% | +2.30% | +3.60% | -34.70% | +16.60% | -26.00% | -2.80% |
Fundamentals
Analyst price target
Technical signals
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 1,480 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.